EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PHF6 mutation is associated with poor outcome in acute myeloid leukaemia

Kexiu Huang iD, Lei Wang, Yaling Zheng, Chunyan Yue, Xuedan Xu, Hongbo Chen, Rui Huang iD, Yuhua Li iD

Cancer Medicine · 2023-02 · 12 (3) · 2795-2804

DOI: 10.1002/cam4.5173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.09.2022. Verfasst von Kexiu Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Zhujiang Hospital of Southern Medical University, Guangzhou, P.R. China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mutation of plant homeodomain finger protein 6 (PHF6) occurs in approximately 3% of acute myeloid leukaemia (AML) cases. Although it was reported to be associated with poor prognosis, it was not confirmed by other groups. Recently, propensity score matching has provided an effective way to minimise bias by creating two groups that are well balanced with respect to baseline characteristics, providing more convincing results, which has an advantage, especially for rare subtype studies. To provide further evidence on the role of PHF6 mutation, we performed a retrospective propensity score‐matched cohort study to assess the therapeutic responses and survival outcomes of AML patients with PHF6 mutation compared with those without PHF6 mutation after balancing age, sex and risk categories. Patients and Methods A total of 22 patients with PHF6 mutation from 801 consecutive newly diagnosed AML cases in our center were identified, and 43 patients with the PHF6 wild‐type genotype were successfully matched at a 1:2 ratio.

Results

AML harbouring PHF6 mutation was associated with a lower complete remission (CR) rate (41% vs. 69%; OR = 3.64, 95% CI 1.10, 12.10; p = 0.035) and shorter median overall survival (OS) (6.0 vs. 39.0 months; p < 0.001) and event‐free survival (EFS) (2.0 vs. 11.0 months; p = 0.013) compared with PHF6 wild‐type patients. Further multivariate analysis supported that PHF6 mutation was an independent risk factor for overall survival in AML (HR = 8.910, 95% CI 3.51, 22.63; p < 0.001). In addition, allogeneic haematopoietic stem cell transplantation (allo‐HSCT) seemed to ameliorate the poor prognosis of AML with PHF6 mutation in this study.

Conclusion

Our data revealed that PHF6 mutation was associated with a lower chemotherapy response and shorter survival, suggesting that PHF6 mutation is a predictor of poor prognosis in AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansRetrospective StudiesCohort StudiesPrognosisMutationRepressor Proteins

Stichwörter der Autor:innen

PDH finger protein 6acute myeloid leukaemiahaematopoietic stem cell transplantationmutationprognosis

Substanzen

PHF6 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Department of Haematology, Zhujiang Hospital of Southern Medical University, Guangzhou, P.R. China.
  • Department of Haematology, Jiangmen Central Hospital, JiangMen, P.R. China.
  • School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, P.R. China.

ORCID-Profile: Kexiu Huang, Rui Huang, Yuhua Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Huang, K., Wang, L., Zheng, Y., Yue, C., Xu, X., Chen, H., Huang, R., & Li, Y. (2023). PHF6 mutation is associated with poor outcome in acute myeloid leukaemia. Cancer Medicine, 12(3), 2795-2804. https://doi.org/10.1002/cam4.5173

Vancouver

Huang K, Wang L, Zheng Y, Yue C, Xu X, Chen H, et al. PHF6 mutation is associated with poor outcome in acute myeloid leukaemia. Cancer Medicine. 2023;12(3):2795-2804. doi:10.1002/cam4.5173

BibTeX
@article{Huang2023,
  author = {Huang, Kexiu and Wang, Lei and Zheng, Yaling and Yue, Chunyan and Xu, Xuedan and Chen, Hongbo and Huang, Rui and Li, Yuhua},
  title = {PHF6 mutation is associated with poor outcome in acute myeloid leukaemia},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {2795--2804},
  doi = {10.1002/cam4.5173}
}
Kostenlos starten →